Longitudinal Lung Function Assessment of Patients Hospitalized With COVID-19 Using ¹H and ¹²⁹Xe Lung MRI.

"Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: The following authors have declarations of support from organizations for the submitted work: P. J. C. H. receives grant funding from GSK and Bayer. A. A. R. T. is funded by British Heart Foundation Intermediate Clinical Fellowship and grant funding from Janssen-Cilag Ltd. A. L. receives grant funding from the British Heart Foundation (fellowship award). R. G. J. receives grant funding from AstraZeneca, Biogen, Galecto, GSK, RedX, Pliant, and Genentech. A. J. S. receives grant funding from the National Institute for Health and Care Research (NIHR) (AI award), Wellcome (Innovator award), and Janssen-Cilag Ltd (project grant). J. M. W. receives grant funding from the Medical Research Council, GSK (investigator led research grant), and GE Healthcare. F. G. receives grant or contract funding from Oxford NIHR Biomedical Research Centre, NIHR (HypErpolarised Xenon Magnetic Resonance PuLmonary Imaging in PAtIeNts with Long-COVID - EXPLAIN), POLAREAN Ltd, and GE Healthcare. K. M. J. has received National Institutes of Health grant funding for the development of an MRI sequence used in this work. The following authors declare financial relationships with organizations that might have an interest in the submitted work in the previous 3 years: A. C. is an employee of GSK and is a shareholder in GSK. F. J. W. was an employee of GSK and was a shareholder in GSK at the time of the study. R F. S. is employed by, and a shareholder of, GE Healthcare. A. L. receives funding support from Janssen-Cilag Ltd for meetings/travel. A. A. R. T. receives funding from Janssen-Cilag Ltd for meetings/travel. R. G. J. receives consulting fees from Bristol Myers Squibb, Daewoong, Veracyte, Resolution Therapeutics, RedX, Pliant, and Chiesi. A. J. S. receives consultancy fees from Janssen-Cilag Ltd. R. G. J. receives payment from Chiesi, Roche, patientMpower, AstraZeneca, GSK, and Boehringer Ingelheim for lectures. A J. S. receives payment for presentations from Janssen-Cilag Ltd. F. G. receives payment for attending a research advice meeting from POLAREAN Ltd. R. G. J. is a trustee of Action for Pulmonary Fibrosis. F. G. is the president of the European Society for Thoracic Imaging. None declared (L. C. S., G. J. C., H.-F. C., L. J. S., J. G. R. W., J. E. M., Z. G., T. N., M. P., J. A. E., S. T., S. S., L. G., H. M., J. B., D. A. C., L. A., J. R., M. B., A. M. B., G. N., O. R., M. R. R., R. M., N. J. S., J. T. G., S. R., G. H. M., R. L., P. J. C., J. E. B., P. W., L. W.)."

"Funding/Support This study was supported by a Medical Research Council grant (MR/M008894/1), a GSK investigator-led grant funding (R/167242-11-1) and a GE Healthcare investigator-led grant funding (R/167303-11-1) to J. M. W. A. A. R. T. was supported by a British Heart Foundation Intermediate Clinical Fellowship (FS/18/13/33281). The study was supported by the NIHR Sheffield Biomedical Research Centre (BRC) / NIHR Sheffield Clinical Research Facility (CRF). Grant funding from the NIHR was received by A. J. S. (AI award: AI_AWARD01706), F. G. (EXPLAIN study: COV-LT2-0049), and K. M. H. for the development of an MRI sequence used in this work (5R01HL136965)."